BAC
ABBV icon

Boys Arnold & Co’s AbbVie ABBV Stock Holding History

Boys Arnold & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-17,445
Closed -$1.33M – 3
2020
Q1 		$1.33M Buy
17,445
+100
+0.6% +$8.52K 0.24% 98
2019
Q4 		$1.54M Buy
17,345
+577
+3% +$47.9K 0.21% 102
2019
Q3 		$1.25M Sell
16,768
-17,447
-51% -$1.2M 0.19% 115
2019
Q2 		$2.49M Sell
34,215
-304
-0.9% -$23.9K 0.36% 70
2019
Q1 		$2.78M Sell
34,519
-522
-1% -$42.7K 0.42% 62
2018
Q4 		$3.19M Buy
35,041
+880
+3% +$77.4K 0.53% 55
2018
Q3 		$3.25M Sell
34,161
-537
-2% -$50.9K 0.45% 56
2018
Q2 		$3.21M Sell
34,698
-250
-0.7% -$24.4K 0.47% 55
2018
Q1 		$3.24M Buy
34,948
+139
+0.4% +$15.3K 0.47% 60
2017
Q4 		$3.37M Buy
34,809
+1,202
+4% +$113K 0.51% 53
2017
Q3 		$2.99M Sell
33,607
-147
-0.4% -$11.2K 0.48% 58
2017
Q2 		$2.45M Buy
33,754
+309
+0.9% +$20.8K 0.32% 69
2017
Q1 		$2.18M Buy
33,445
+329
+1% +$20.7K 0.34% 78
2016
Q4 		$2.07M Buy
33,116
+506
+2% +$30.9K 0.34% 78
2016
Q3 		$2.06M Buy
32,610
+21
+0.1% +$1.36K 0.35% 79
2016
Q2 		$2.02M Buy
32,589
+27,379
+526% +$1.67M 0.35% 79
2016
Q1 		$298K Sell
5,210
-27,588
-84% -$1.54M 0.12% 127
2015
Q4 		$1.94M Buy
32,798
+1,216
+4% +$70K 0.21% 113
2015
Q3 		$1.72M Sell
31,582
-1,852
-6% -$121K 0.36% 83
2015
Q2 		$2.25M Sell
33,434
-10
-0% -$653 0.44% 69
2015
Q1 		$1.96M Sell
33,444
-250
-0.7% -$15.1K 0.37% 81
2014
Q4 		$2.21M Buy
33,694
+3,331
+11% +$210K 0.43% 73
2014
Q3 		$1.75M Sell
30,363
-1,205
-4% -$66.9K 0.35% 84
2014
Q2 		$1.78M Buy
31,568
+150
+0.5% +$7.87K 0.31% 86
2014
Q1 		$1.61M Buy
31,418
+500
+2% +$25.3K 0.29% 85
2013
Q4 		$1.63M Sell
30,918
-2
-0% -$98 0.31% 81
2013
Q3 		$1.38M Sell
30,920
-8,996
-23% -$399K 0.29% 87
2013
Q2 		$1.65M Buy
+39,916
New +$1.75M 0.36% 78

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Boys Arnold & Co's ABBV Position: Q2 2020 in Review

Boys Arnold & Co sold out of AbbVie (ABBV) in Q2 2020, closing a stake of 17,445 shares — an estimated $1.33M sold.

Boys Arnold & Co first reported a position in ABBV in Q2 2013 and held it in 28 quarters. The position peaked at $3.37M in Q4 2017. 2,412 funds tracked by Wall St. Rank hold ABBV as of Q2 2020.

  • Boys Arnold & Co reported no remaining AbbVie position as of Q2 2020 after selling out during the quarter.
  • Boys Arnold & Co sold 17,445 AbbVie shares in Q2 2020, an estimated $1.33M.
  • Boys Arnold & Co first reported a position in AbbVie in Q2 2013 and held it in 28 quarters.
  • Boys Arnold & Co's AbbVie position peaked at $3.37M in Q4 2017.
  • 2,412 funds tracked by Wall St. Rank held AbbVie as of Q2 2020.

Based on Boys Arnold & Co's 13F filing for Q2 2020.